Company ProfilePremium

Wide Open Agriculture Limited

Company Profile Analysis

Ticker: WOA.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Wide Open Agriculture Limited - Company showcase

Year Founded & Workforce

2015

Wide Open Agriculture Limited logo

Wide Open Agriculture Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Wide Open Agriculture Limited Overview

Wide Open Agriculture is a Perth-based, ASX-listed ingredient technology company that is trying to turn the Australian sweet lupin, a legume that Western Australia grows in large quantities but which is mostly used as stock feed, into a high-value food, beverage, cosmetic and nutraceutical ingredient. Its core asset is intellectual property: an exclusive global licence from Curtin University over a lupin protein modification process, patents and know-how acquired from Germany's Prolupin, and newer filings such as a lupin protein milk formulation. Having exited its Dirty Clean Food consumer business in 2024 and shut its owner-operated German plant in 2026, WOA is now a capital-light IP owner seeking contract manufacturers in Asia. It also aims to monetise the whole seed through protein isolate, oil and fibre. Revenue remains sub-A$1 million, cash was A$1.27 million at 30 June 2026, and the company's survival depends on converting a customer pipeline and securing low-cost manufacturing.


What the company does today

WOA develops, specifies and sells lupin-derived ingredients to business customers. Data aggregators drawing on the company's descriptions summarise the current offer as lupin protein isolates, lupin oil and fibre, and gamma conglutin. These are sold to food manufacturers, ingredient distributors and other business customers through B2B ingredient sales and tolling production services. The geographic markets cited are Australia, Europe, North America, South America and Asia (StockAnalysis / Simply Wall St company descriptions, 2026).

Market Index carries the company's current self-description. It positions WOA as a listed ingredient company pioneering lupin-based products for the food, beverage, cosmetics and nutraceutical sectors. It claims proprietary IP across the production process and a portfolio of lupin proteins, fibres, oil and other compounds intended to improve product functionality and performance.

Company's own description (FY2026 Appendix 4E, paraphrased)

The FY2026 review describes the year as a strategic transition. The company says it appointed a commercially experienced CEO and Chair, advanced commercialisation of its proprietary lupin ingredient technologies, strengthened customer and distribution relationships, expanded its IP and progressed a "whole-of-seed" product model. A detailed review of manufacturing economics led to a decision to move from owner-operated manufacturing to an asset-light contract manufacturing model, while retaining the technology, IP and commercial relationships. Management states its objective as becoming a globally relevant supplier of differentiated, high-performance lupin-based ingredients through a capital-efficient operating model.

Business model and revenue model

Revenue streamStatus (FY2026)NatureComment
Lupin protein isolate sales (B2B)Moderated; production in Germany reduced and then haltedProduct8 customers and more than 30 commercial launches secured by the end of FY2026 (FY2026 Appendix 4E). Supply to existing customers must be re-established via contract manufacturing
Third-party toll manufacturingCompleted; ended with German wind-downServicePea protein contract production for a non-competitive customer; A$230k of toll income in the December 2025 quarter alone. This was the main revenue driver in FY2026 and sits in discontinued operations
Lupin oilInitial small sale (cosmetics)ProductFirst commercial sale to a European cosmetics company in the December 2025 quarter; hypoallergenic testing announced 30 July 2026
Lupin fibreDevelopment / characterisationProduct (future)Company declared a fibre product commercially ready in an earlier announcement; testing supporting commercial potential announced 6 August 2026
Technology licensing / royaltiesNot yet a revenue streamLicensing (inbound)WOA pays Curtin University a flat 3.5% royalty on net sales (revised May 2026). It does not currently earn licensing income
Grants and R&D tax incentiveMaterial "other income"Non-operatingOther income of A$2.60M in FY2026 (continuing), including A$2.26M of R&D tax incentive refunds for FY2024 and FY2025 and A$0.29M of grant income

Independent characterisation: WOA is best described as a pre-commercial ingredient technology company with a residual operating history. Statutory revenue (A$0.83M in FY2026 including discontinued operations) is dwarfed by its cost base, and in FY2026 the R&D tax incentive and grants exceeded revenue by roughly three times. The mix today is product (protein, oil) plus a now-ceased service line (tolling). There is no subscription revenue, and licensing is inbound rather than outbound. The intended future model resembles an "IP-owning brand manufacturer": WOA retains formulations, process know-how, product specifications and customer relationships, while contract manufacturing organisations (CMOs) in Asia carry the capital-intensive processing. In the long term, management is studying a 10,000 tonne-per-annum (tpa) owned facility in Western Australia (estimated capex about A$311M, unfunded).

Value chain position

Value chain stageWOA role (2026)
Lupin farming (WA Wheatbelt)Sources seed from growers; no longer farms at scale (regenerative farming heritage via Wide Open Land Pty Ltd)
Primary processing (dehulling, milling, de-oiling)Outsourced / to be outsourced to CMOs
Protein extraction, fractionation, dryingProprietary process IP (Curtin licence, Prolupin patents); execution to move to CMOs
Ingredient specification and application developmentCore in-house capability
B2B sales and distributionDirect sales plus distributors (Univar Solutions China; Proeon Foods with conditional India distribution rights)
Consumer brandExited (Dirty Clean Food sold April 2024)

Customer types and end-markets

Customer types disclosed are ingredient distributors, food manufacturers and consumer brands seeking novel plant proteins (FY2025 Appendix 4E). In addition, a European cosmetics company bought lupin oil, and pea protein toll customers were served in Germany. End-markets targeted include plant-based dairy alternatives (lupin milk, barista and beverage applications), sports and medical nutrition beverages (Univar China rollout in beverage and nutrition), bakery and other foods, cosmetics and personal care (lupin oil), and dietary fibre (lupin fibre).

Strategy

Stated strategy: "Building Better Economics" (announced 2 Jul 2026; restated in FY2026 Appendix 4E)

StageThemeSpecific actionsStatus (Oct 2026)
Stage 1Wind down owner-operated manufacturingOrderly wind-down of the German plant; remove fixed cost and capital burdenUnderway; WOAG in administration
Stage 2Transition to contract manufacturingCapital-light CMO model for lupin protein isolate; target about 500–1,000 tpa scaled to demand; Asia preferred; retain IP, specifications and customer relationshipsFour non-binding framework agreements signed (Proeon, VLS, OMN9, Haldin); about 95 CMOs screened; 12+ NDAs; definitive agreement targeted within calendar 2026
Stage 3Build value from the whole lupin seedCommercialise protein as the core; develop lupin oil and fibre; increase value recovered per tonne; improve sustainability credentials and gross marginLupin oil: first sale plus hypoallergenic testing. Fibre: testing supports commercial potential
Stage 4Plan for large-scale industrial productionComplete PFS/study for a 10,000+ tpa WA facility; invest only with demonstrated demand, unit economics, funding, regulatory and board approvalStudy released 6 Oct 2026 (capex about A$311M ±30%); DFS planned for 2027; FID targeted mid-2028; first production 2031 at the earliest

Strategic initiatives in the last 24 months

InitiativeDateDescription
Univar Solutions China rolloutSep 2025 quarterLaunch of WOA lupin protein in China's beverage and nutrition sectors; later constrained by manufacturing cost
Lupin Sustainability StudySep 2025 quarterIndependently reviewed study of lupin farming and WOA isolate; concluded lupins can contribute materially to GHG reductions
WA facility PFSCommenced Sep 2025 quarterEvolved into the Industrial Scale Manufacturing Study (Oct 2026)
Lupin protein milk formulation22 Oct 2025New patent filing for beverage applications
China market entry (CIIE)Nov 2025Joined the Australian delegation to the China International Import Expo
Lupin oil commercialisationDec 2025 quarter onwardFirst sale to European cosmetics; hypoallergenic test results (30 Jul 2026); skin care potential claims (Oct 2026)
Leadership renewalMar–May 2026New CEO (Swan) and Chair (Brown)
Curtin royalty restructure25 May 2026Flat 3.5% royalty replaces a tiered structure
Contract manufacturing transitionJul–Sep 2026Four framework agreements across India, Vietnam and Indonesia
Cost programmeJul 2026 onwardGerman wind-down; deferral of board and executive fees; reduced marketing and R&D spend
Alternative processing technology trialsJune 2026 quarterProduction trial of lupin protein isolate using an alternative processing technology; technical work on de-oiling, fractionation, purification and drying

Medium-term targets and guidance

TargetDetail
CMO production volumeAbout 500–1,000 tpa of lupin protein isolate
CMO partnerExecute a definitive contract manufacturing partnership within calendar 2026
Industrial facilityDFS 2027; FID mid-2028; about 30 months of construction; first production 2031 at the earliest
Financial guidanceNone provided. No revenue, margin or profitability targets

Products & Services

Current portfolio (lupin ingredients)

Product / brandDescriptionKey capabilities (as disclosed)Target customerLaunch / statusPricing
Buntine Protein® (lupin protein; also marketed as lupin protein isolate)Flagship plant protein from Australian sweet lupin using a Curtin University-developed modification processThe technology unfolds the lupin protein to improve its ability to gel, thicken and blend, which addresses lupin's historic taste, texture and gelling limitations (Market Index news, 2022). Positioned for plant-based dairy, meats, baked goods and health foods; patent-protected globallyFood and beverage manufacturers, ingredient distributorsPilot production in WA in 2022; commercial isolate from Germany from 2024; production moderated in FY2026 and halted in July 2026—
Lupin protein isolate (Prolupin-derived process)Isolate produced at the Grimmen plant using patents that originated at the Fraunhofer Institute (acquired by Prolupin in 2010)Strong position in plant-based dairy applications; regulatory approvals obtained in EuropeEuropean dairy-alternative and nutrition brandsAcquired April 2024; production wound down from July 2026—
Luve (trademark)Prolupin's consumer-facing lupin brand, previously sold in European retailTrademark acquired with Prolupin assetsEuropean consumers / brand licenseesAcquired 2024; current commercial use not disclosed—
Lupin protein milk formulationProprietary lupin protein milk for beverage applicationsPatent application filed in FY2026Dairy-alternative and beverage brandsAnnounced 22 October 2025—
Lupin oilOil co-product from de-oiling lupin seedIndependent testing reported it as hypoallergenic (30 July 2026); company claims skin care potentialCosmetics and personal careFirst commercial sale to a European cosmetics firm in the Dec 2025 quarter—
Lupin fibreDietary fibre co-product from protein extractionDeclared commercial-ready in an earlier announcement; testing supporting commercial potential (6 August 2026)Food manufacturers (fibre fortification, bakery)Development / characterisation—
Gamma conglutinBioactive lupin protein fractionListed in aggregator descriptions of WOA's offer; specific claims not disclosed in sources reviewedNutraceuticalsStatus not disclosed—
Toll manufacturing servicesContract processing of third-party proteins (pea) at GrimmenHelped recover overheads during start-upNon-competing protein brandFY2025–FY2026; completed in the June 2026 quarter—

Planned industrial-scale product slate (6 Oct 2026 study)

ProductModelled annual output at nameplate (tonnes)
Lupin protein isolate10,000
Dried lupin fibre17,500
Filtered lupin oil730
Lupin hulls11,900

Source: Industrial Scale Manufacturing Study, as reported by Kalkine on 6 October 2026. The company states that modelled revenue of A$240–295M a year at full capacity is not a forecast and that volumes are uncontracted.

Divested / discontinued portfolio (historical)

Product / brandDescriptionPeriodDisposition
Dirty Clean Food (DCF)"Soil-to-table" regenerative food brand: beef, lamb, poultry, seafood, eggs, bakery items, fruit and vegetables, pantry staples, ready meals (pizza, cheeseboards); online retail, food service and independent supermarkets in WA2019–Apr 2024Sold to DCF Global Pty Ltd (Jay Albany) for A$1.5M
Dirty Clean Food Oat Milk / OatUPOat milk positioned as carbon-neutral; barista and retail formats; exported via distributors (DKSH Taiwan, GrowHub)2021–2024Transferred with DCF
Oat-milk ice creamVegan ice cream sold through Perth independent retailers2021–2024Transferred with DCF
Buntine Protein high-protein oat milk and snacksDCF products featuring WOA lupin protein2022–2024Transferred with DCF

Financial Narrative

Basis of preparation: Australian Accounting Standards / IFRS. FY2023 and FY2024 figures are from the FY2024 Appendix 4E. FY2025 and FY2026 figures are from the FY2026 Appendix 4E (FY2025 restated). FY2022 figures are partly from secondary sources and are flagged accordingly. FY2026 figures are unaudited.

Income statement

Notes:

  • FY2022 revenue (about A$9.3M) is from SmallCaps' coverage of the FY2022 results.

  • FY2024 net loss: A$12.74M per the preliminary (unaudited) report; the FY2025 report shows the FY2024 comparative as A$13.25M. FY2025 net loss: A$7.09M per the FY2025 preliminary report; restated to A$6.89M in the FY2026 report.

  • FY2024 EPS of -7.40c is derived as -3.17c (continuing) plus -4.23c (discontinued).

  • EBITDA is derived as pre-tax loss plus depreciation, amortisation and finance costs. FY2025 and FY2026 EBITDA are on a continuing-operations basis only. FY2026 continuing EBITDA is flattered by A$2.26M of R&D tax refunds covering two years.

  • FY2024 includes A$1.20M of impairment of fixed assets and a A$1.36M loss on sale of business. FY2025 continuing includes A$0.54M of impairment of plant and equipment.

Margins and growth (%)

Derived. FY2025 EBITDA and net margins use continuing EBITDA over continuing revenue, and group net loss over as-reported revenue (A$0.469M), respectively. FY2026 EBITDA margin uses continuing EBITDA over continuing revenue; net margin uses group loss over group revenue including discontinued operations.

Revenue CAGR FY2022–FY2026 (as reported): approximately -45% per year (A$9.3M to A$0.83M, derived). This figure reflects the deliberate exit from consumer food rather than organic decline. On a lupin-protein-only basis, revenue rose from A$0.07M (FY2024) to A$0.47M (FY2025) and A$0.83M (FY2026), but the FY2026 figure was mostly toll processing of pea protein.

Balance sheet

Notes:

  • FY2022 cash and equity are taken from the FY2023 opening balances in the FY2024 Appendix 4E. SmallCaps reported A$19.7M of cash at June 2022 from the quarterly report.

  • FY2024 cash of A$1.99M includes A$2.61M of share subscription money received in advance and held in trust. Underlying cash at bank was a A$0.62M overdraft.

  • FY2026 cash is A$1.20M in the balance sheet; A$1.27M including cash in assets held for sale. Assets held for sale were A$0.61M; liabilities held for sale A$0.14M (WOAG).

Cash flow

FY2024 equity issued includes A$7.60M of net share proceeds plus A$2.61M received in advance. The FY2025 net change shown is on a restated basis.

Ratios

All ratios are derived. ROIC, net debt/EBITDA and interest coverage are not meaningful: EBITDA and EBIT are negative and the company holds net cash. The cash conversion cycle is not meaningful given negative gross margins and the absence of steady-state working capital disclosure.

Commentary on trends, inflections and drivers

Phase 1 — consumer-led growth (FY2019–FY2023). Revenue grew in an unbroken run of quarterly increases (12 consecutive quarters to June 2022), reaching A$9.3M in FY2022 and A$11.46M in FY2023. Growth was driven by Dirty Clean Food's expansion across WA independent grocers, food service and online, and by oat milk launches. Unit economics were poor throughout. FY2023 gross margin was only 6.2% (A$0.71M gross profit on A$11.46M revenue), and selling expenses (A$2.49M) and employee costs (A$7.21M) produced a loss of A$14.66M. The company burned A$13.3M of free cash flow in FY2023 alone, taking cash from A$19.5M to A$5.9M. This was the decisive inflection that forced the strategic reset.

Phase 2 — pivot and acquisition (FY2024). The divestment of DCF to its own CEO for A$1.5M, payable over five years, crystallised a A$1.36M loss on sale. DCF contributed A$7.28M to the FY2024 loss. At the same time, WOA spent A$4.19M acquiring Prolupin's German assets out of insolvency and booked A$1.20M of fixed asset impairments. The balance sheet was weakest at this point: working capital was negative (-A$0.56M), the current ratio was 0.88x, and the bank account was in overdraft but for A$2.61M of subscription monies held in trust.

Phase 3 — scaling attempt at negative margins (FY2025). As a pure lupin business, revenue rose more than six-fold to A$0.47M but gross margin was deeply negative (gross loss of A$0.34M as reported). Two equity raisings (A$6.14M of shares issued, A$5.70M net cash) funded operating outflows of A$3.49M. The restated FY2025 figures show the German operation losing A$3.09M on about A$0.25M of revenue.

Phase 4 — retrenchment (FY2026). The FY2026 group loss fell 47% to A$3.64M. Continuing operations lost only A$0.73M, but that was because other income of A$2.60M included two years of R&D tax refunds (A$2.26M) and A$0.29M of grant income from the Department of Energy & Economics. Underlying continuing cash burn before grants was about A$3.4M (operating outflow of A$0.89M plus A$2.55M of grants received). Management attributed the German losses to rising energy and labour costs, a fixed-cost base and low established capacity. The decision on 2 July 2026 to wind down Germany removes the largest source of losses but also nearly all revenue. Cash of A$1.27M at 30 June 2026 represented about 2.1 quarters of funding (Food & Drink Business, June 2026 quarterly). Management's response includes deferring part of board and executive fees and limiting near-term marketing and R&D spend.

Equity erosion: Cumulative issued capital of A$60.7M has been offset by accumulated losses of A$58.1M. Shareholders' equity of A$2.86M equals about 0.43 cents of NTA per share.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Reported Segments by Period

PeriodReported segmentsNotes

FY2019–FY2023

Effectively one operating business (Dirty Clean Food), with plant protein development as an emerging activity

In FY2022 Dirty Clean Food accounted for essentially all revenue (SmallCaps)

FY2024

Plant protein operations; Dirty Clean Food business

Segment naming per Pearler/Morningstar-derived description. DCF was discontinued on 23 April 2024

FY2025 (as originally reported)

Single lupin protein business (Australia corporate/R&D plus German manufacturing)

No associates or JVs

FY2026 (and FY2025 restated)

Continuing operations (Australian parent: commercial, R&D, corporate) and Discontinued operations (Wide Open Agriculture Germany GmbH)

WOAG placed into administration; FY2025 restated

Revenue by Segment

SegmentFY2023FY2024FY2025FY2026

Dirty Clean Food (discontinued Apr 2024) (AUD Mn, derived)

11.468.9200

Plant protein, continuing (Australian parent) (AUD Mn)

00.070.220.12

Plant protein, Germany (WOAG, discontinued 2026) (AUD Mn, derived)

0—0.250.70

Total group revenue incl. discontinued (AUD Mn)

11.468.990.470.83

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Results by Segment

Segment resultFY2024FY2025FY2026

Continuing operations loss after tax (AUD Mn)

-5.46-3.80-0.73

Discontinued operations loss after tax (AUD Mn)

-7.28-3.09-2.91

Group loss after tax (AUD Mn)

-12.74-6.89-3.64

Segment Margins & Growth (%) and Revenue by Segment (%)

MetricFY2025FY2026

Continuing gross margin (%)

-244-353

Continuing revenue share of group (%)

4715

Germany revenue share of group (%)

5385

Group revenue YoY growth (%)

-9576

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue, as originally reported (AUD Mn)

9.3011.468.990.470.83

Revenue, continuing ops latest basis (AUD Mn)

——0.070.220.12

Gross profit, as reported (AUD Mn)

—0.710.70-0.34—

Gross profit, continuing ops restated (AUD Mn)

———-0.53-0.44

Other income (AUD Mn)

—0.773.381.632.60

Operating income before finance costs, derived (AUD Mn)

—-14.61-12.57-3.71-0.72

EBITDA, derived (AUD Mn)

-10.10-13.86-11.57-3.18-0.17

Pre-tax income (AUD Mn)

-10.80-14.66-12.74-6.89-3.64

Income tax expense (AUD Mn)

00000

Net income, group (AUD Mn)

-10.80-14.66-12.74-6.89-3.64

Net income, continuing ops (AUD Mn)

—-14.66-5.46-3.80-0.73

Basic EPS, group (A cents)

—-10.27-7.40-1.29-0.56

Diluted EPS, group (A cents)

—-10.27-7.40-1.29-0.56

Dividends per share (A cents)

00000

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue growth, as reported (%)

11523-21-9576

Gross margin, as reported (%)

—6.27.8-72.1—

Gross margin, continuing ops (%)

———-244.1-352.8

EBITDA margin (%)

-108.6-121.0-128.7-1,448.6-137.1

Net margin, group (%)

-116.1-128.0-141.7-1,469.6-440.8

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (AUD Mn)

—15.4010.228.583.34

Cash and equivalents (AUD Mn)

19.475.871.993.391.20

Short-term borrowings (AUD Mn)

—0.110.500.020

Long-term borrowings (AUD Mn)

—0.59000

Lease liabilities, total (AUD Mn)

—2.010.540.820.01

Total debt incl. leases (AUD Mn)

—2.711.040.850.01

Net debt, negative = net cash (AUD Mn)

—-3.16-0.95-2.54-1.19

Total equity (AUD Mn)

23.9810.115.206.282.86

Goodwill and intangibles (AUD Mn)

—01.210.160.03

Property, plant and equipment (AUD Mn)

—3.814.222.610.12

Current assets (AUD Mn)

—9.334.003.892.54

Current liabilities (AUD Mn)

—3.134.561.740.45

Working capital, derived (AUD Mn)

—6.20-0.562.152.09

Issued capital (AUD Mn)

44.3844.6352.2360.5160.70

Accumulated losses (AUD Mn)

-24.48-39.14-51.88-56.02-58.11

NTA per share (A cents)

—7.064.570.920.43

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (AUD Mn)

—-11.87-9.25-3.49-2.15

of which grants / R&D refunds received (AUD Mn)

—0.412.781.342.55

Capex (AUD Mn)

—-1.44-0.58-0.01-0.01

Free cash flow, derived (AUD Mn)

—-13.31-9.83-3.50-2.17

Acquisitions (AUD Mn)

—0-4.1900

Proceeds from sale of business (AUD Mn)

—00.1500

Equity issued, net (AUD Mn)

—0.1610.215.700.20

Dividends paid (AUD Mn)

00000

Share buybacks (AUD Mn)

00000

Net change in cash (AUD Mn)

—-13.62-3.640.93-2.12

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2023FY2024FY2025FY2026

ROE, on average equity (%)

-86-166-120-80

ROA, on average assets (%)

-95-99-73-61

Current ratio (x)

2.980.882.245.70

Debt to equity, incl. leases (x)

0.270.200.130.003

Asset turnover (x)

0.740.700.050.14

Revenue by Region

Region (entity-based proxy)FY2023FY2024FY2025FY2026

Australia (AUD Mn)

11.468.990.220.12

Europe / Germany (AUD Mn)

0—0.250.70

Total (AUD Mn)

11.468.990.470.83

Region Margins & Growth (%)

Region (proxy)FY2025FY2026

Australia growth (%)

-98-43

Europe / Germany growth (%)

—181

Country / Region Details

Country / regionActivity disclosedPeriod

Australia

Corporate HQ, R&D, Curtin licence, proposed 10,000 tpa facility; product launches in FY2025

Ongoing

Germany / EU

Grimmen plant (2024–2026); first lupin oil sale to a European cosmetics firm; lupin protein launches in Europe in FY2025

Wound down from Jul 2026

China

Univar Solutions China commercial rollout (beverage and nutrition), constrained by supply cost; CIIE participation

FY2026

South America

Product launches during FY2025 (customers not named)

FY2025

United States

—

FY2024–FY2025

India

Proeon Foods: conditional exclusive distribution rights; Shree Ram Agro / OMN9 framework

Aug–Sep 2026

Vietnam

Vietnam LifeScience Company framework, including a conditional five-year exclusive manufacturing clause

Sep 2026

Indonesia

PT Haldin Pacific Semesta framework

Sep 2026

Taiwan

DKSH Taiwan oat milk distribution (DCF era)

2022–2024

Capital Markets

MeasureValueSource

Recent trading range (Mar–Aug 2026)

A$0.007 – A$0.016

ASX announcement price records (InvestSMART)

52-week range (as of May 2026)

About A$0.01 – A$0.03

Halo Technologies

1-year performance vs ASX 200

-55.2% relative

Market Index

Performance since IPO (as of Aug 2025)

About -92%

Stoxray

Frankfurt (2WO)

€0.0015 (26 Jun 2026); 52-week range €0.0015 – €0.0135

StockAnalysis

Share Price

MetricJul 2025Mar 2026May 2026Jul 2026Aug 2026

Share price (AUD)

0.0160.0160.0120.0090.010

Valuation Multiples

MultipleWOA

Market capitalisation (AUD Mn)

5.9

Enterprise value (AUD Mn)

about 4.6 (market cap less A$1.27M cash)

EV / Sales FY2026 (x)

about 5.6

P/E

Not meaningful (losses)

EV / EBITDA

Not meaningful (negative EBITDA)

P/B (x)

about 2.1 (equity A$2.86M)

Price / NTA (x)

about 2.1 (NTA 0.43c)

Capital Markets — Analyst consensus

ItemDetail

Analyst consensus

None. Not covered by major brokers (Market Index)

Dividend history

No dividends ever paid; none proposed for FY2026

Dividend policy

No dividends while loss-making

Credit ratings (Moody's, S&P, Fitch)

Not rated

Debt maturity profile

No borrowings at 30 June 2026; lease liabilities of A$9,250 (current)

Listed options

WOAO

Capital raising history (recent)

FY2024: A$7.60M net plus A$2.61M in advance; FY2025: A$6.14M of shares issued (A$5.70M net cash); FY2026: A$0.23M of shares issued

Analyst Conclusions

Management guidance

Management has given no quantitative financial guidance. Stated FY2027 priorities are to complete the orderly German wind-down, establish contract manufacturing to re-supply existing customers, convert pipeline activity into sales, and develop protein, fibre and oil under the whole-of-seed model. Capital will be tied to demand, near-term marketing and R&D will be limited, and some fees and salaries will be deferred (FY2026 Appendix 4E). Operational targets are about 500–1,000 tpa via CMOs and a definitive CMO agreement within calendar 2026. For the long-term WA facility, the DFS is planned for 2027, FID for mid-2028 and first production no earlier than 2031.

Consensus expectations

There is no consensus, as no analysts cover the stock.

Bull case

  1. Capital-light reset unlocks unit economics. Exiting Germany removes the business that lost A$2.91M in FY2026 (and A$3.09M in FY2025). If an Asian CMO can make isolate at a positive gross margin, the 8 customers and more than 30 launches already secured provide a ready base for revenue.

  2. Whole-seed margin stacking. Oil (hypoallergenic, cosmetic-grade) and fibre raise value per tonne. The industrial study shows that co-products would exceed protein by volume (about 17,500 t of fibre against 10,000 t of isolate).

  3. Asymmetric valuation. At an enterprise value of about A$4.6M, the market ascribes little value to an exclusive global IP platform with improved royalty terms, four CMO frameworks, and Univar (China) and Proeon (India) distribution pathways.

Bear case

  1. Funding cliff. Cash of A$1.27M against about 2.1 quarters of funding means further dilutive raises are near-certain, at prices around one cent per share.

  2. Track record of value destruction. DCF (A$11.5M revenue in FY2023 at a 6% gross margin) was sold for A$1.5M on deferred terms. The Prolupin plant (A$4.19M) was closed about two years after completion. Accumulated losses of A$58.1M nearly equal the A$60.7M of capital raised.

  3. No manufacturing, no revenue. All four CMO agreements are non-binding. Continuing revenue was only A$0.12M in FY2026, customer supply has lapsed, and the A$311M industrial plant is unfunded and at least five years away.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timingWhy it matters
September 2026 quarterly (Appendix 4C)By end Oct 2026Cash balance, burn rate and German wind-down costs
FY2026 audited Annual Report / auditor's going-concern opinionSep–Oct 2026Confirms unaudited figures; going-concern emphasis
2026 AGMLikely Nov 2026Board re-election, capital authority (e.g. Listing Rule 7.1A placement capacity)
Definitive CMO agreementTargeted within calendar 2026Core to re-establishing supply
Capital raisingLikely within 1–2 quartersSize, price and investor quality
First CMO-produced lupin isolate and customer re-supply2,027Validates the new model
Outcome of WOAG administration, including ownership of Prolupin patents and Luve trademark2026–2027IP perimeter and residual liabilities
Univar China volume restart2,027Largest named commercial channel
Lupin oil and fibre sales2026–2027Evidence for whole-seed economics
Collection of DCF deferred considerationOngoingRelated-party receivable
DFS funding decision for WA facility2,027Long-term option value

Analyst verdict

Wide Open Agriculture is no longer the regenerative food company its name implies. After three strategic resets in four years, it has become a lupin ingredient IP company with almost no operating footprint. The FY2026 numbers show both the logic and the weakness of the reset. The group loss fell 47% to A$3.64M and the balance sheet is debt-free. But continuing revenue was just A$0.12M, the improvement leaned on A$2.26M of two-year R&D refunds, and cash of A$1.27M covers only about two quarters.

The investment case now depends on one question: can a third-party manufacturer in Asia produce WOA's lupin isolate at a cost that supports a positive gross margin? WOA's own attempts at the Perth pilot plant and the Grimmen facility did not. Since July 2026 the new leadership team, led by a CEO with credible B2B ingredient experience, has moved quickly. It renegotiated the Curtin royalty, signed four IP-protective framework agreements across three countries, produced evidence for oil and fibre co-products, and published an industrial-scale study. These are sensible steps, but none is yet binding or revenue-generating.

The stock trades at roughly 2x NTA and about 5–6x trailing sales. That valuation reflects option value on the IP platform rather than any underlying earnings. Near-term dilution looks unavoidable, and the history of capital destruction (A$58M of accumulated losses) argues for scepticism until a definitive CMO contract and first re-supply orders are announced.

**Overall assessment: speculative / high-risk. The key downgrade trigger would be a qualified going-concern opinion combined with any delay to the CMO timetable beyond early 2027.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior roles / background

Craig Swan

Chief Executive Officer

Since 7 Apr 2026

More than 30 years in B2B food ingredients, including senior roles at Goodman Fielder Ingredients, NutraSweet and Givaudan (ASX announcement, 3 Mar 2026)

CFO / Company Secretary

——

Not identified in sources reviewed.

Board of Directors

NameRoleAppointedBackgroundIndependenceDisclosed holding (Market Index)

Justin Brown

Non-Executive Chair

May 2026

The company cites significant capital markets experience and a record of developing and executing growth strategies at ASX-listed companies

Not formally disclosed in sources reviewed

1,760,994 shares; 3,869,565 options (4 May 2026)

Matthew Skinner

Non-Executive Director

NED since Mar 2026

CFO from FY2023; interim CEO from Mar 2024; CEO until Apr 2026

Not independent (former executive within three years)

854,768 shares; 2,475,440 options (3 Mar 2026)

Vincent Lauwerier

Non-Executive Director

Dec 2025 quarter

Not detailed in sources reviewed

——

Jack Guidry

Non-Executive Director

FY2026 (holding notice dated 4 May 2026)

Not detailed in sources reviewed

—

400,000 shares (4 May 2026)

“—” = not publicly disclosed.

Board of Directors — Yaxi Zhan

NameFormer roleDepartureContext

Yaxi Zhan

Chair

May 2026

Replaced by Justin Brown in the board renewal

Anthony Maslin

Founding director (former Chair)

May 2026

Co-founder; exit from the board ends founder representation

Claudia Kwan

Non-Executive Director

Mar 2026 (appointed Sep 2025 quarter)

Stepped down for personal and professional reasons; remains a strategic adviser on investor and partnership opportunities

Executive Leadership Team — Dr Ben Cole

NameRolePeriod

Dr Ben Cole

Co-founder; Managing Director

2015 – c. Holds about 5.9M shares (0.90%) plus 5.0M (Market Index)

Anthony Maslin

Co-founder; Founding Chair, later director

2015 – May 2026

Stuart McAlpine

Non-Executive Director

Early years (described as former director by 2022)

Jay Albany

CEO, Dirty Clean Food, then Group CEO

Group CEO Dec 2022 – Mar 2024 (left to buy DCF)

Matthew Skinner

CFO, then interim CEO, then CEO

FY2023 – Apr 2026

Major Shareholders

Holder typeDetail

Institutional ownership

Not publicly disclosed; no substantial institutional holders identified

Insider ownership (identified)

Justin Brown 1.76M shares; Matthew Skinner 0.85M; Jack Guidry 0.40M; Ben Cole (founder, not a director) about 10.9M across two holdings. Identified insiders hold roughly 2% of about 654M shares (derived)

Competitive Landscape

Key Competitors

CompetitorSegmentRelationship to WOAScale (approximate)Positioning

Roquette (France, private)

Pea protein isolates

Direct substitute in plant-based dairy, meat and nutrition

Multi-billion-euro revenue

Global leader in pea protein; scale cost advantage

Cargill (US, private; including PURIS partnership)

Pea and other plant proteins

Substitute

Over US$100B group revenue

Integrated supply chain; global customer access

ADM (NYSE: ADM)

Soy, pea and specialty proteins

Substitute

Tens of billions of US$

Broad portfolio and flavour systems

Ingredion (NYSE: INGR)

Pulse proteins (pea, faba)

Substitute

Multi-billion US$

Texturiser and protein solutions

Cosucra (Belgium, private)

Pea protein, chicory fibre

Substitute (protein and fibre)

Mid-size

European pulse specialist; competes on fibre too

Burcon NutraScience (TSX: BU)

Pea, canola and other novel isolates

Closest listed analogue (IP-led plant protein developer)

Small

Process IP and partner-manufacturing model, similar to WOA's new model

Australian Plant Proteins (private, Victoria)

Faba/pulse protein isolates

Australian regional competitor

Small

Domestic pulse isolate capacity

Soy protein producers (various)

Soy isolates

Commodity benchmark

Very large

Lowest-cost incumbent protein

Australian lupin flake and flour processors (e.g. Coorow Seeds)

Lupin flour and flakes

Competes for food-grade lupin demand

Small

Lower-processed lupin foods

Former Prolupin brand ecosystem (Germany)

Lupin isolate

Acquired by WOA; EU lupin start-ups continue to emerge

Small

WOA's German exit leaves an opening for other EU lupin processors

Proeon Foods (as a competitor)

Mung bean and peanut isolates

Now a framework partner; competes in plant protein generally

Small

Note potential conflict, mitigated by IP clauses

Peer Comparison FY2026

MetricWOA FY2026Large pulse protein majors

Revenue

0.83

Billions

Revenue growth

+76% (group, mixed basis)

Low single digits typical

Gross margin

Negative (-353% continuing)

Positive

Company Snapshot

2015

Founded

Leederville, Australia

Headquarters

SWOT Analysis

Strengths

  • Proprietary, exclusive IP. WOA holds an exclusive global licence to Curtin University's lupin protein technology, retained in the May 2026 amendment that cut the royalty to a flat 3.5% of net sales.
  • Commercial proof points. By 30 June 2026 the company had 8 customers and more than 30 commercial launches (FY2026 Appendix 4E), with launches in South America, Europe and Australia during FY2025.
  • Whole-seed optionality. First commercial lupin oil sale (Dec 2025 quarter), hypoallergenic test results (Jul 2026) and fibre testing (Aug 2026) give three product lines beyond protein.
  • Clean balance sheet. Zero borrowings and only A$9,250 of lease liabilities at 30 June 2026; net cash of A$1.19M.
  • Experienced new leadership. CEO Craig Swan brings more than 30 years in B2B ingredients (Goodman Fielder Ingredients, NutraSweet, Givaudan).
  • Strong non-dilutive funding access. A$2.55M of grants and R&D refunds received in cash in FY2026, exceeding revenue three-fold.

Weaknesses

  • Negative gross margins. Continuing gross loss of A$0.44M on A$0.12M of revenue in FY2026 (-353%).
  • Tiny revenue base. Group revenue of A$0.83M in FY2026, 85% from a German entity now in administration.
  • Thin liquidity. Cash of A$1.27M at 30 June 2026, about 2.1 quarters of funding.
  • History of capital destruction. A$60.7M of issued capital against A$58.1M of accumulated losses; NTA fell from 7.06c (FY2023) to 0.43c (FY2026).
  • Failed owned manufacturing. The A$4.19M Prolupin acquisition (FY2024) was wound down roughly two years after completion.
  • Governance instability. Four CEOs or interim CEOs since 2022 (Cole, Albany, Skinner, Swan); three board departures and three appointments in FY2026.

Opportunities

  • Asian contract manufacturing. Four framework agreements across India, Vietnam and Indonesia could lower unit costs. The VLS clause offers five-year exclusivity once more than 50 tonnes are produced.
  • China via Univar. The existing commercial rollout could resume once low-cost supply is available.
  • India via Proeon. Conditional exclusive distribution rights in India.
  • Cosmetics. Hypoallergenic lupin oil could earn higher margins per tonne than protein.
  • Industrial-scale facility. Modelled revenue of A$240–295M a year at 10,000 tpa (not a forecast) would be transformational if funded.
  • Protein price inflation. Management cites rising global protein price realisation, which would improve lupin's relative competitiveness.

Threats

  • Going-concern and dilution risk. Small cash balance and a micro-cap share price of around A$0.01 make any raise highly dilutive.
  • IP leakage. Transfer of know-how to Asian CMOs that also produce plant proteins (Proeon: mung bean and peanut). The protections run for five years post-term but enforcement abroad is untested.
  • Customer attrition. Supply to the 8 existing customers was interrupted during the transition.
  • Allergen labelling. Lupin's allergen status constrains mainstream food adoption.
  • Commodity incumbents. Pea and soy isolates from Roquette, Cargill and ADM set the price benchmark.
  • Feedstock volatility. Lupin prices fluctuate (noted by management historically) and WA crops are exposed to drought.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
May 2025Capital raising (first of two in May and July 2025)Extended runway; dilution
Jul 2025Second capital raising trancheFY2025 shares issued of A$6.14M in total
29 Aug 2025FY2025 preliminary results: revenue A$468,870; loss A$7.09M; gross loss A$0.34MRevenue up about 541% on a protein-only basis; loss roughly halved
30 Sep 2025FY2025 Annual Report releasedStatutory filing
Sep 2025 qtrUnivar Solutions China begins commercial rolloutFirst meaningful Asian channel
Sep 2025 qtrLupin Sustainability Study releasedESG differentiation
Sep 2025 qtrWA facility Pre-Feasibility Study commencedLong-term scale option
Sep 2025 qtrClaudia Kwan appointed NEDGovernance
22 Oct 2025Lupin protein milk formulation announcedNew IP
31 Oct 2025September quarterly: cash about A$2.0M; lower burn expected; R&D rebates anticipatedLiquidity
Nov 2025Joins Australian delegation to CIIE (China)Market development
Late 20252025 AGM heldGovernance
Dec 2025 qtrFirst lupin oil sale to a European cosmetics companyValidates whole-seed model
Dec 2025 qtrVincent Lauwerier appointed NEDBoard
30 Jan 2026December quarterly: cash A$1.5M; operating outflow A$0.5M; toll income A$230k; related party payments A$51kLiquidity tightening
3 Mar 2026Craig Swan named CEO (effective 7 Apr); Skinner moves to NED; Kwan steps downLeadership change
9 Apr 2026R&D Tax Incentive rebate (about A$1.69M) receivedNon-dilutive liquidity
23 Apr 2026March quarterly: German lupin protein production reduced on cost; contract manufacturing model under investigation; higher toll revenuePrecursor to the pivot
5 May 2026Board renewal: Justin Brown becomes Chair; Yaxi Zhan and Anthony Maslin departGovernance reset
25 May 2026Curtin University royalty restructured to a flat 3.5%Better unit economics
2 Jul 2026"Transition to Contract Manufacturing for Improved Economics": German wind-down; Asia CMO target of 500–1,000 tpaStrategic pivot; shares rose about 86% on the day (A$0.007 to A$0.013)
7 Jul 2026Investor presentation releasedMarket communication
28 Jul 2026June quarterly: cash A$1.274M (about 2.1 quarters of funding); about 90 CMOs identified, 12 NDAs; pea protein tolling completedGoing-concern pressure
30 Jul 2026Independent testing shows WOA lupin oil is hypoallergenicCo-product validation
6 Aug 2026Testing supports commercial potential of WOA lupin fibreCo-product validation
10 Aug 2026Non-binding framework agreement with Proeon Foods B.V.First CMO framework
31 Aug 2026FY2026 preliminary results: loss A$3.64M (down 47%); WOAG placed into administrationFinancial reset
Sep 2026Three further framework agreements (VLS, OMN9, Haldin)CMO optionality
Late Sep 2026Audit / going concern opinion is a key watch item
6 Oct 2026Industrial Scale Manufacturing Study: 10,000 tpa isolate; capex about A$311M; modelled revenue A$240–295M a year (not a forecast)Long-term vision; unfunded
Oct 2026Cosmetic market positioning

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue, as originally reported fell from AUD 9.3 Mn in FY2022 to AUD 0.8 Mn in FY2026.
Wide Open Agriculture Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue, as originally reported9.311.590.50.8
Revenue, continuing ops latest basis——0.10.20.1
Gross profit, as reported—0.70.7-0.3—
Gross profit, continuing ops restated———-0.5-0.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. WOA FY2026 Preliminary Final Report (Appendix 4E) — 31 Aug 2026 — FY2025–FY2026 financials, strategy, board, operations
  2. WOA FY2025 Preliminary Final Report — 29 Aug 2025 — FY2025 results, narrative
  3. WOA FY2024 Preliminary Final Report — 2 Sep 2024 — FY2023–FY2024 financials, DCF disposal
  4. ASX quarterly and price-sensitive announcement summaries (InvestSMART) — Oct 2025 – Aug 2026 — Newsflow, cash balances, appointments
  5. Kalkine — Industrial Scale Manufacturing Study coverage — 6 Oct 2026 — Capex, capacity, timetable
  6. SmallCaps / TradingView — Three framework agreements — Sep 2026 — CMO partners and terms
  7. Vegconomist; Food Ingredients First; Protein Production Technology — Aug 2026 — Proeon agreement
  8. Food & Drink Business — Jul–Aug 2026 — June 2026 quarterly, CMO search
  9. Just Food; Business News Australia — Feb–Mar 2024 — DCF sale terms
  10. Grain Central; ProteinReport; Vegconomist — Oct 2023 — Prolupin acquisition
  11. SmallCaps; Market Index news; Stockhead — 2020–2022 — Early history, revenue, Curtin licence, pilot plant
  12. Market Index; Google Finance; Simply Wall St; StockAnalysis; Halo; Stoxray — 2025–2026 — Market data, auditor, holdings, listing date
  13. IBISWorld; CB Insights — 2025–2026 — Incorporation date, addresses

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.